Goldman Sachs
ACRS icon

Goldman Sachs’s Aclaris Therapeutics ACRS Stock Holding History

Goldman Sachs’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150,000
Closed -$3.87M – 6298
2017
Q3 		$3.87M Buy
150,000
+15,000
+11% +$402K ﹤0.01% 3394
2017
Q2 		$3.66M Buy
135,000
+40,000
+42% +$1.09M ﹤0.01% 3319
2017
Q1 		$2.83M Buy
+95,000
New +$2.74M ﹤0.01% 3417

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs's ACRS Position: Q1 2026 in Review

Goldman Sachs reduced its Aclaris Therapeutics (ACRS) stake by 6.9% in Q1 2026, selling an estimated $148K and leaving 588,691 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #4454.

Goldman Sachs first reported a position in ACRS in Q1 2017 and has held it in 37 quarters since. The position peaked at $7.94M in Q3 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Goldman Sachs held 588,691 shares of Aclaris Therapeutics worth $2.21M as of Q1 2026.
  • Goldman Sachs sold 43,811 Aclaris Therapeutics shares in Q1 2026, an estimated $148K.
  • Aclaris Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4454 holding.
  • Goldman Sachs first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Goldman Sachs's Aclaris Therapeutics position peaked at $7.94M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.